NorthStrive Biosciences Expands AI-Driven Drug Discovery Program with Yuva Biosciences, Advancing Four Novel AI-Discovered Compounds Toward Lead Nomination for Potential Cardiac Disease and Obesity Therapeutic Applications

Building on positive Phase III results from the parties' AI-driven drug discovery program, the six-month Expansion Program will narrow the four validated compounds toward a nominated lead and designated backup.

The Amendment also strengthens the exclusive Cardiac Disease and Obesity field of use and adds a right of first refusal across the broader cardiometabolic field.